There isn’t a single “Alzheimer’s gene,” but several genes strongly influence your risk. The most important is APOE, which comes in different versions. One version, called APOE e4, doubles or triples your risk of developing late-onset Alzheimer’s if you carry one copy. If you inherit two copies (one from each parent), your risk jumps to 8 to 12 times higher than someone without it. But carrying APOE e4 doesn’t guarantee you’ll develop the disease, and many people with Alzheimer’s don’t carry it at all.
A separate, rarer set of gene mutations does virtually guarantee Alzheimer’s, but these cause a different form of the disease that strikes decades earlier. Understanding which genes do what, and how much they actually matter, can help you make sense of your own family history.
The APOE Gene and Late-Onset Risk
The APOE gene provides instructions for making a protein that helps transport cholesterol and fats in the brain. Everyone inherits two copies, one from each parent, and the gene comes in three common versions: e2, e3, and e4. Most people carry the e3 version, which is considered neutral. The e4 version is the one linked to higher Alzheimer’s risk.
What makes e4 problematic is how it handles a sticky protein fragment called amyloid beta, which accumulates in the brains of people with Alzheimer’s. The brain has cleanup systems that clear this debris. The protein made by the e3 version does a better job activating those cleanup processes: it helps immune cells in the brain engulf and digest amyloid, and it facilitates moving the protein out through the blood-brain barrier. The e4 version is less effective at both tasks. It’s slower to trigger immune cell cleanup, and amyloid bound to the e4 protein gets cleared through the blood-brain barrier at a substantially lower rate. On top of that, the e4 version can actually damage the blood-brain barrier itself, further compromising the brain’s ability to remove waste.
Roughly 25% of people carry at least one copy of APOE e4, so this is not rare. But it’s important to understand that it’s a risk factor, not a destiny. Plenty of people with one or two copies of e4 never develop Alzheimer’s, and roughly half of all Alzheimer’s patients don’t carry e4 at all.
The Protective Version: APOE e2
While e4 raises risk, the e2 version of APOE appears to lower it. People with one copy of e2 paired with one copy of e3 have the lowest observed risk of late-onset Alzheimer’s. One large genetic analysis estimated that roughly 23% of Alzheimer’s cases could be attributed to the absence of an e2 allele in the population. Only about 8% of people carry at least one copy of e2, making it the least common version.
Genes That Cause Early-Onset Alzheimer’s
A completely different genetic picture exists for early-onset Alzheimer’s, which develops before age 65 and sometimes as early as the 30s. Three genes are responsible: PSEN1, PSEN2, and APP. Mutations in any of these genes can directly cause the disease, not just increase risk. These mutations follow an autosomal dominant inheritance pattern, meaning if a parent carries one, each child has a roughly 50% chance of inheriting it.
PSEN1 mutations are the most common cause and tend to produce the earliest symptoms, sometimes in a person’s 30s or 40s. In families where these mutations run, the pattern is often unmistakable: multiple relatives developing dementia at unusually young ages. In documented cases, siblings carrying the same PSEN1 mutation developed memory loss and cognitive symptoms within a few years of each other, both before age 55.
These deterministic mutations are rare. Early-onset Alzheimer’s accounts for a small fraction of all cases, and even among early-onset patients, only about 35% to 60% have a clear family history suggesting a genetic cause. The rest appear to be sporadic, with no identifiable family pattern.
Beyond APOE: Other Risk Genes
Large-scale genetic studies scanning the DNA of hundreds of thousands of people have identified dozens of additional locations in the genome that slightly nudge Alzheimer’s risk up or down. A recent study of over 205,000 Alzheimer’s cases identified 30 new risk regions, bringing the running total of known genetic hotspots well past 75. Individually, each of these contributes only a small amount of risk. Collectively, they help explain why Alzheimer’s runs in some families even when APOE e4 isn’t involved.
One gene that has attracted particular attention is TREM2, which makes a receptor on the surface of the brain’s immune cells (microglia). This receptor acts as a master regulator, helping microglia find and engulf amyloid plaques, shift from an inflammatory state to a calmer one, and prune damaged connections between neurons. A specific variant of TREM2 called R47H roughly triples Alzheimer’s risk. When TREM2 function is impaired, microglia lose much of their ability to clean up toxic proteins and instead ramp up inflammation, which accelerates damage.
What Genetic Testing Can Tell You
Genetic testing for Alzheimer’s falls into two categories with very different implications. Testing for PSEN1, PSEN2, and APP mutations is most informative in families where multiple relatives developed dementia before age 65. A positive result in those cases is highly predictive. Guidelines from the American College of Medical Genetics recommend that an affected family member be tested first when possible, and that all testing happen alongside genetic counseling from a specialist who can help interpret results and provide psychological support.
Testing for APOE status is more complicated. Because carrying e4 doesn’t determine whether you’ll get Alzheimer’s, and because not carrying it doesn’t protect you, the clinical usefulness of knowing your APOE type is limited. Professional guidelines generally recommend against APOE testing for people without symptoms, noting its poor predictive value for any individual. Direct-to-consumer genetic tests that report APOE status can cause significant anxiety without providing actionable medical guidance. If you do pursue testing, doing so through a healthcare provider who can put results in context is the more useful path.
Lifestyle Factors and Genetic Risk
One of the more encouraging findings in recent years is that lifestyle interventions appear to help even people who carry APOE e4. The Finnish Geriatric Intervention Study (FINGER trial) tested a combination of diet improvements, exercise, cognitive training, and cardiovascular risk management in over 1,200 older adults at elevated dementia risk. APOE e4 carriers who received the intervention showed statistically significant improvements in overall cognitive scores and memory compared to e4 carriers who didn’t, suggesting that genetic risk doesn’t make lifestyle changes pointless. If anything, the data hinted that carriers might benefit more from these interventions, though confirming that will require larger studies.
This is a meaningful finding because it reframes genetic risk as something you can push back against. Your genes load the odds, but they don’t seal the outcome. Physical activity, cardiovascular health, mental engagement, and diet all remain modifiable factors regardless of what version of APOE you carry.